Pfizer has received approval from the EC for updates to the Summary of Product Characteristics (SmPC) for pneumococcal conjugate vaccine Prevenar 13 (sold as Prevnar 13 in the U.S.). The updated label now includes information describing the use of the vaccine in preterm infants, children and adolescents with sickle cell disease who were previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine, and adults with human immunodeficiency virus (HIV) infection who were previously va...